HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Biocon’s partner secures multiple insulin contracts in Malaysia
Jun-24-2026

Biocon’s long-standing partner -- Duopharma Biotech Berhad (Duopharma Biotech) has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over 225 million Malaysian ringgit this year. Duopharma Biotech has secured the contracts through its wholly-owned subsidiary -- Duopharma (M) Sendirian Berhad. As part of these contracts, the company’s subsidiary -- Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.

The contracts comprise a three-year agreement valued at around 155.27 million Malaysian ringgit for human insulin, along with two 2-year agreements: around 18 million Malaysian ringgit for insulin glargine and around 52.5 million Malaysian ringgit for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

  RELATED NEWS >>